0000950170-24-084003.txt : 20240716 0000950170-24-084003.hdr.sgml : 20240716 20240716180031 ACCESSION NUMBER: 0000950170-24-084003 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240715 FILED AS OF DATE: 20240716 DATE AS OF CHANGE: 20240716 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Gollob Jared CENTRAL INDEX KEY: 0001821198 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39460 FILM NUMBER: 241120583 MAIL ADDRESS: STREET 1: C/O KYMERA THERAPEUTICS, INC. STREET 2: 200 ARSENAL YARDS, SUITE 230 CITY: WATERTOWN STATE: MA ZIP: 02472 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Kymera Therapeutics, Inc. CENTRAL INDEX KEY: 0001815442 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 812992166 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 500 NORTH BEACON STREET, 4TH FLOOR CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: 857-285-5314 MAIL ADDRESS: STREET 1: 500 NORTH BEACON STREET, 4TH FLOOR CITY: WATERTOWN STATE: MA ZIP: 02472 4 1 ownership.xml 4 X0508 4 2024-07-15 0001815442 Kymera Therapeutics, Inc. KYMR 0001821198 Gollob Jared C/O KYMERA THERAPEUTICS, INC. 500 NORTH BEACON STREET, 4TH FLOOR WATERTOWN MA 02472 false true false false Chief Medical Officer true Common Stock 2024-07-15 4 M false 16455 2.08 A 112195 D Common Stock 2024-07-15 4 S false 16455 45.1489 D 95740 D Common Stock 2024-07-16 4 M false 23145 2.08 A 118885 D Common Stock 2024-07-16 4 S false 13281 45.5931 D 105604 D Common Stock 2024-07-16 4 S false 9864 46.0965 D 95470 D Stock Option (Right to Buy) 2.08 2024-07-15 4 M false 16455 0.00 D 2029-05-22 Common Stock 16455 46028 D Stock Option (Right to Buy) 2.08 2024-07-16 4 M false 23145 0.00 D 2029-05-22 Common Stock 23145 22883 D These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 22, 2023 adopted by the reporting person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.52, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.02 to $46.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.02 to $46.35, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The shares underlying this stock option vest in forty-eight (48) equal monthly installments following the vesting commencement date of February 7, 2019, subject to the reporting person's continued employment through each vesting date. /s/ Bruce Jacobs, as Attorney-in-Fact 2024-07-16